AstraZeneca’s antibody against a strain of Covid-19 which was previously linked to the Wuhan variant of the virus retained neutralising activity, according to an independent US Food and Drug Administration (FDA) study published in the journal The Lancet.
Source: pharmiweb.comPublished on 2021-12-21
Related news
- New Analyses of Two AZD7442 COVID - 19 Phase III Trials in High - Risk Populations Confirm Robust Efficacy and Long - Term Prevention
- AstraZeneca COVID - 19 and RSV presentations at IDWeek 2021 will showcase scientific progress in infectious diseases
- Continued attendance in a PrEP program despite low adherence and non - protective drug levels among adolescent girls and young women in Kenya : Results from a prospective cohort study
- AZD7442 reduced risk of developing severe COVID - 19 or death in TACKLE Phase III outpatient treatment trial
- Energistics Becomes an Affiliate of The Open Group® Following Completion of Governance Transition
- NREL Offers U . S . Power Sector Scenarios with Grid Impacts and Uncertainties
- UAE - Energistics Becomes an Affiliate of The Open Group® Fo ...
- AstraZeneca plc ( via Public ) / AZD7442 reduced risk of developing severe COVID - 19 or death in TACKLE Phase III outpatient treatment trial
- The Role of Technology on a Student - Centered Campus
- Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC : AZD7442 PhIII trial positive in COVID outpatients
- NSF - funded institute at Georgetown University aims to advance research around viral emergence
- TrackTik launches Data Lab for companies to manage their data
- EVUSHELD long - acting antibody combination retains neutralizing activity against Omicron variant in studies from Oxford and Washington Universities
- EVUSHELD long - acting antibody combination retains neutralizing activity against Omicron variant in studies from Oxford and Washington Universities
- Forecasting U . S . Renewable Energy Adoption to 2050